← Back to Search

Motivational Refinements for Decreasing Destructive Behavior

N/A
Recruiting
Led By Brian D Greer, Ph.D.
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 4 weeks.
Awards & highlights

Study Summary

This trial aims to improve destructive behavior treatments to reduce risk of harm & improve outcomes for those affected by it.

Who is the study for?
This trial is for boys and girls aged 3-17 with developmental disabilities who exhibit destructive behaviors reinforced by social consequences, occurring at least 10 times a day. They must be on a stable drug regimen or drug-free, with no changes in educational placement expected during the study.Check my eligibility
What is being tested?
The trial tests two enhancements to Functional Communication Training (FCT) aimed at reducing destructive behavior: one speeds up reinforcement schedule thinning using progressive interval assessment; another adds competing stimuli to prevent relapse.See study design
What are the potential side effects?
Since this trial involves behavioral interventions rather than medications, traditional side effects are not applicable. However, there may be an increase in destructive behavior during the transition phases of treatment adjustments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 4 weeks.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 4 weeks. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Destructive behavior (responses per minute)
Discriminated functional communication responses (percentage)
Efficiency of schedule thinning

Trial Design

3Treatment groups
Experimental Treatment
Group I: Evaluation of PIA-Informed Schedule ThinningExperimental Treatment2 Interventions
The goal of Arm 1 will be to will extend pilot work on the utility of individualizing the starting point for reinforcement schedule thinning based on the results of a progressive-interval assessement (PIA). The investigators will do so by conducting reinforcement schedule thinning using a multielement design in two separate contexts, one informed by the results of a PIA and another not so informed. The criteria for schedule thinning will be identical across both conditions but will be applied to each condition independently. Investigators will determine the efficiency of schedule thinning, reductions of destructive behavior, and durability of functional communication responses across the two conditions.
Group II: Evaluation of Competing ItemsExperimental Treatment2 Interventions
The goal of Arm 2 will be to evaluate the utility of competing items (e.g., alternative reinforcement or activities) during schedule thinning. Both conditions will be informed by the PIA, similar to the experimental condition in Arm 1. PIA-informed schedule thinning with competing stimuli will be identical to that of PIA-informed schedule thinning, except (a) the therapist will provide continuous access to the highly competing stimulus identified by that participant's competing stimulus assessment (e.g., providing attention while an iPad is unavailable, playing music while working), and (b) it will occur in the other context (e.g., the yellow context). Investigators will determine the efficiency of schedule thinning, reductions of destructive behavior, the durability of functional communication responses across the two conditions, and resurgence of destructive behavior during prolonged periods of extinction.
Group III: Effects of Competing Items on PIA OutcomesExperimental Treatment1 Intervention
The goal of Arm 3 will be to examine potential interaction effects between the above two experimental arms by conducting PIAs with no, low, moderate, and high competing stimuli to determine the schedule duration at which schedule thinning should commence with each competing stimulus. All participants will complete this arm prior to enrollment in Arms 1 or 2. The investigators will randomize the sequence of each of the four PIAs (PIA with no competing stimuli, PIA with low competing stimuli, PIA with moderately competing stimuli, PIA with highly competing stimuli) across participants.

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor
429 Previous Clinical Trials
64,202 Total Patients Enrolled
Brian D Greer, Ph.D.Principal InvestigatorRutgers, The State University of New Jersey
1 Previous Clinical Trials
4 Total Patients Enrolled

Media Library

PIA-Informed Schedule Thinning Clinical Trial Eligibility Overview. Trial Name: NCT05790668 — N/A
Increasing Functional Communication Research Study Groups: Evaluation of PIA-Informed Schedule Thinning, Effects of Competing Items on PIA Outcomes, Evaluation of Competing Items
Increasing Functional Communication Clinical Trial 2023: PIA-Informed Schedule Thinning Highlights & Side Effects. Trial Name: NCT05790668 — N/A
PIA-Informed Schedule Thinning 2023 Treatment Timeline for Medical Study. Trial Name: NCT05790668 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals of any age being considered for this experiment?

"According to the requirements, candidates must be aged 3-17 if they wish to take part in this clinical trial."

Answered by AI

Who qualifies to partake in this research endeavor?

"The protocol of this trial necessitates that applicants display a decrease in disruptive conduct and be between 3 to 17 years old. In total, 30 people are being sought for inclusion."

Answered by AI

Is the research project currently accepting volunteers?

"Per the information available on clinicaltrials.gov, this trial is not currently accepting patients. The initial postdate was July 1st 2023 and the latest update was March 17th 2023; meanwhile, two other studies are actively recruiting participants at this time."

Answered by AI
~20 spots leftby May 2028